

Shah et al

## **Elevated D-Dimer Levels are Associated with Increased Risk of Mortality in COVID-19: A Systematic Review and Meta-Analysis**

Siddharth Shah MD<sup>1</sup>, Kuldeep Shah MD<sup>2</sup>, Siddharth B Patel, MBBS, MPH<sup>3</sup>, Forum S Patel MPH<sup>4</sup>, Mohammed Osman<sup>2</sup>, MD, Poonam Velagapudi MD<sup>5</sup>, Mohit K. Turagam MD<sup>6</sup>, Dhanunjaya Lakkireddy MD<sup>7</sup>, Jalaj Garg MD FACC FESC<sup>8</sup>

1. Department of Cardiology, State University of New York Upstate Medical University, Syracuse, NY
2. Division of Cardiology, West Virginia University, Morgantown, WV
3. Department of Pulmonary, allergy and critical care, University of Alabama, Birmingham, AL
4. Department of Infectious Diseases, University of Alabama, Birmingham, AL
5. Division of Cardiology, University of Nebraska Medical Center, Omaha, Nebraska
6. Helmsley Electrophysiology Center, Icahn School of Medicine at Mount Sinai, New York, NY
7. Kansas City Heart Rhythm Institute and Research Foundation, Overland Park, KS
8. Division of Cardiology, Cardiac Arrhythmia Service, Medical College of Wisconsin, Milwaukee, WI

**Short Title:** D-dimer in COVID-19

**Word Count:** Abstract – 232; Manuscript – 2,673; Figure – 5; Tables - 4

**Conflict of Interest:** None

**Funding Source:** None

Shah et al

**Corresponding Author**

Jalaj Garg MD FACC FESC  
Division of Cardiology, Cardiac Arrhythmia Service  
Medical College of Wisconsin  
10000 Innovation Drive  
Milwaukee, WI 53226  
P: 414-955-6737  
F: 414-955-0069  
Email: [garg.jalaj@yahoo.com](mailto:garg.jalaj@yahoo.com)

Shah et al

## Abstract

**Introduction.** The 2019 novel Coronavirus (2019-nCoV), now declared a pandemic has an overall case fatality of 2-3% but it is as high as 50% in critically ill patients. D-dimer is an important prognostic tool, often elevated in patients with severe COVID-19 infection and in those who suffered death. In this systematic review, we aimed to investigate the prognostic role of D-dimer in COVID-19 infected patients.

**Methods.** We searched PubMed, Medline, Embase, Ovid, and Cochrane for studies reporting admission D-dimer levels in COVID-19 patients and its effect on mortality.

**Results.** 18 studies (16 retrospective and 2 prospective) with a total of 3,682 patients met the inclusion criteria. The pooled mean difference (MD) suggested significantly elevated D-dimer levels in patients who died versus those survived (MD 6.13 mg/L, 95% CI 4.16 – 8.11,  $p < 0.001$ ). Similarly, the pooled mean D-dimer levels were significantly elevated in patients with severe COVID-19 infection (MD 0.54 mg/L, 95% CI 0.28 – 0.8,  $p < 0.001$ ). In addition, the risk of mortality was four-fold higher in patients with positive D-dimer vs negative D-dimer (RR 4.11, 95% CI 2.48 – 6.84,  $p < 0.001$ ) and the risk of developing the severe disease was two-fold higher in patients with positive D-dimer levels vs negative D-dimer (RR 2.04, 95% CI 1.34 – 3.11,  $p < 0.001$ ).

**Conclusion.** Our meta-analysis demonstrates that patients with COVID-19 presenting with elevated D-dimer levels have an increased risk of severe disease and mortality.

**Keywords:** 2019-nCoV, D-dimer, severe COVID-19, mortality.

Shah et al

## **Introduction**

The 2019 novel Coronavirus (2019-nCoV) or Severe Acute Respiratory Syndrome Corona Virus 2 (SARS-CoV-2), now declared a pandemic, first originated in December 2019 in Wuhan city of Hubei province, China and has since caused a significant impact on mankind <sup>1</sup>. As of April 24th, 2020, 2.6 million individuals have been infected with SARS-CoV-2 in 213 countries worldwide, and 181,938 lives have been lost <sup>2</sup>. On December 31st, 2019, China reported the outbreak to the World Health Organization (WHO). Subsequently, WHO officially declared the Coronavirus disease 2019 (COVID-19) epidemic as a public health emergency of international concern.<sup>3</sup> The clinical features of COVID-19 vary from asymptomatic cases to severe infection, causing acute respiratory distress syndrome (ARDS), multisystem organ dysfunction, and death <sup>4</sup>.

The overall case fatality rate (CFR) for COVID-19 was reported at about 2% in China. Still, it was noted to be higher at 7.2% in Italy, which was felt secondary to the higher mean age of the overall population <sup>5</sup>. The CFR is significantly high in patients with severe COVID-19 infection with CFR as high as >50% in patients admitted to the Intensive Care Unit (ICU) <sup>6</sup>. Due to high mortality in critically ill COVID-19 patients, the detection of biomarkers which may help identify them earlier in their course of illness can be crucial. D-dimer is one such biomarker that has emerged as an important prognostic tool, with elevated levels in critically ill patients and those deceased. In this systematic review, we aimed to investigate the prognostic role of admission D-dimer levels in patients hospitalized with COVID-19.

## **Methods**

### *Search strategy*

Shah et al

The reporting of this systematic review and meta-analysis complies with PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analysis) guidelines (**Supplement Table 1**)<sup>7</sup>.

The initial search strategy was developed by two authors (SS and SP). We performed a systematic search, without language restriction, using PubMed, EMBASE, SCOPUS, Google Scholar, and two preprint servers (<https://www.medrxiv.org/> and <https://www.ssrn.com/index.cfm/en/coronavirus/>) from inception to April 16th, 2020, for studies that reported D-dimer levels in COVID-19 patients. We utilized the “related articles” function in PubMed to find relevant articles that were missed by the initial search. In addition, reference lists of the included studies were hand-searched to further locate relevant articles that were missed in the primary search. We used the following keywords and medical subject heading: "COVID-19", "SARS-CoV-2", "Wuhan coronavirus", "Coronavirus 2019", "2019 n-CoV", "D-dimer", "laboratory".

#### *Study Selection and data extraction*

To be included in our systematic review and meta-analysis the study had to fulfill the following criteria: (1) reported D-dimer levels in COVID-19 patients according to severity or include mortality as a clinical outcome; (2) included human subjects. (3) studies in English language. Single-arm studies, case reports, editorial, or systematic reviews were excluded. Two investigators (SS and SP) independently performed the literature search and screened all titles and full-text versions of all relevant studies that met study inclusion criteria.

The data from included studies were extracted using a standardized protocol and a data extraction form. Any discrepancies between the two investigators were resolved with a

Shah et al

consultation with the senior investigator (JG). Two independent reviewers (SS and SP) extracted the following data from the eligible studies: author name, study design, publication year, follow-up duration, number of patients, age, gender, diabetes mellitus (DM), hypertension (HTN), coronary artery disease (CAD), acute cardiac injury, arrhythmias, shock, and outcomes. The Newcastle Ottawa Risk bias assessment tool was used to appraise the quality of the included studies (**Supplement Table 2**).

## **Outcomes**

### *Clinical outcomes*

The primary outcome of interest in our study was all-cause mortality and severity of COVID-19.

## **Statistical Analysis**

Mantel-Haenszel risk ratio (RR) random-effects model (DerSimonian and Laird method) was used to summarize data between the groups<sup>8</sup>. The D-dimer levels in the studies were reported as median and Interquartile Range (IQR). We used the Wan method to estimate the mean and standard deviations<sup>9</sup>. We then calculated the pooled difference in means (MD) to evaluate the association of levels of D-dimer between the groups. Higgins I-squared ( $I^2$ ) statistic was used to assess the test of heterogeneity. A value of  $I^2$  of 0–25% represented insignificant heterogeneity, 26–50% represented low heterogeneity, 51–75% represented moderate heterogeneity, and more than 75% represented high heterogeneity<sup>10</sup>. A pre-specified random-effects meta-regression analysis was conducted for the primary outcome in relation to the baseline demographics, comorbid condition, biomarkers to test the relationship between D-dimer and disease severity, and all-cause mortality. Publication bias was formally assessed using

Shah et al

funnel plots and Egger's linear regression test of funnel plot asymmetry. A two-tailed  $p < 0.05$  was considered statistically significant. Statistical analysis was performed using Comprehensive Meta-Analysis version 3.0 (Biostat Solutions, Inc. [BSSI], Frederick, Maryland).

## Results

### *Search results*

A total of 920 citations were identified during the initial search (**Figure 1**). Nine hundred and two records were excluded. After a detailed evaluation of these studies, 12 studies met the inclusion criteria. We included six manuscripts from 2 pre-print servers (<https://www.medrxiv.org/> and <https://www.ssrn.com/index.cfm/en/coronavirus/>), to accommodate the rapidly evolving nature of information for COVID. We acknowledge that the manuscripts from these two sources are not peer-reviewed. Eighteen articles including 3,682 patients were included in the final analysis.

### *Study characteristics*

This systematic review and meta-analysis of 18 studies incorporated a total of 3,682 patients. Six articles compared D-dimer levels upon admission in dead versus survived patients<sup>11-16</sup>, one article compared patients with elevated D-dimer level with normal D-dimer level<sup>17</sup> and 11 articles compared severe versus non-severe COVID-19 patients<sup>18-28</sup>. All studies were retrospective<sup>12-27</sup> except two which were prospective<sup>11, 28</sup> and all were conducted in China, in the year 2020.

Positive d-dimer was defined as levels  $\geq 0.5\text{mg/L}$ . Severe COVID-19 disease was defined as patients with respiratory rate  $\geq 30$  beats/minute (resting state) or mean oxygen saturation of

Shah et al

$\leq 93\%$  on room air or an arterial blood oxygen partial pressure (PaO<sub>2</sub>)/oxygen concentration (FiO<sub>2</sub>)  $\leq 300$  mm Hg and was consistent across all studies. The severe group included patients with severe COVID-19 and those needing ICU care for acute respiratory failure requiring mechanical ventilation, or for shock, or multiorgan failure. The acute cardiac injury was defined as an elevation in cardiac troponin or new changes of ischemia on electrocardiography (ECG) or new wall motion abnormalities on an echocardiogram.

**Table 1** summarizes the baseline characteristics of 6 studies which compared dead versus survived patients and 1 study which compared patients with elevated D-dimer vs normal D-dimer level. Among the 6 studies which compared dead versus survived patients, the mean age of the study population in this group was  $62.5 \pm 14.8$  years and 56.3% were males. Overall, hypertension (HTN) was the most common comorbidity (36.6%), followed by diabetes (DM) (16.8%) and coronary artery disease (CAD) (11.7%). The acute cardiac injury was present in 19.3% of patients while shock was observed in 8.9% of patients. New-onset arrhythmias of some form were observed in 12% of patients.

**Table 2** summarizes the baseline characteristics of 11 studies that compared severe versus non-severe COVID-19 patients. The mean age of the study population in this group was  $49.9 \pm 17.2$  years and 54.6% were males. Overall, HTN was the most common comorbidity (18.8%), followed by DM (9.2%) and CAD (3.9%). The acute cardiac injury was present in 11% of patients while shock was observed in 3.6% of patients, of which, 2% of patients have septic shock while it was undefined in other patients.

### *All-cause mortality*



Shah et al

The data for D-dimer levels were available in 5 studies<sup>11, 13-16</sup>. The pooled mean D-dimer levels were significantly elevated in patients who died versus those who survived (MD 6.13 mg/L, 95% CI 4.16 – 8.11,  $p \leq 0.001$ ,  $I^2 = 81.41\%$ ) (**Figure 2**). No publication bias was observed (Egger's  $P = 0.39$ , **Supplement Figure 1**). Meta-regression analysis demonstrated no significant associations were found between age, male sex, hypertension, diabetes, coronary artery disease, C-Reactive Protein, and troponins in COVID-19 infected patients who died versus who survived (**Table 3**).

The risk of mortality was four-fold in patients with positive D-dimer vs. negative D-dimer (21% vs 4.9%, RR 4.11, 95% CI 2.48 – 6.84,  $p \leq 0.001$ , respectively). Test of heterogeneity was non-significant ( $I^2 = 0\%$ ) (**Figure 3**). No publication bias was observed (Egger's  $P = 0.26$ , **Supplement Figure 2**).

### ***Severity of COVID-19***

The data for D-dimer levels were available in 9 studies<sup>19-25, 27, 28</sup>. The pooled mean D-dimer levels were significantly elevated in patients with severe COVID-19 infection (MD 0.54 mg/L, 95% CI 0.28 – 0.8,  $p \leq 0.001$ ,  $I^2 = 90.74\%$ ) (**Figure 4A**). No publication bias was observed (Egger's  $P = 0.13$ , **Supplement Figure 3**). Meta-regression analysis showed a significant association between CAD, C-Reactive Protein, and severe COVID-19 disease, but the results were not significant for age, male sex, comorbidities (hypertension, diabetes, troponin levels) (**Table 4, Figures 4B and 4C**).

The risk of developing the severe disease was two-fold higher in patients with positive D-dimer levels vs negative D-dimer (40.74% vs. 21.98%, RR 2.04, 95% CI 1.34 – 3.11,  $p \leq 0.001$ ,  $I^2 = 81.83\%$ , respectively) (**Figure 5**). No publication bias was observed (Egger's  $P = 0.16$ ,

Shah et al

**Supplement Figure 4).** A sensitivity analysis was performed by removing one study at a time (n-1 analysis) to investigate the significant heterogeneity. No significant change in the findings was observed with the sensitivity analysis.

## Discussion

Elevated D-dimer is one of the abnormal laboratory parameters in patients with COVID-19 infection. D-dimer is the fibrin degradation products released upon cleavage of crosslinked fibrin by plasmin<sup>29</sup>. Historically, the role of D-dimer is limited due to its non-specificity, with elevated levels are often seen with advanced age, African American race, female sex, active malignancy, surgery, pregnancy, immobility, cocaine use, connective tissue disorders, end-stage renal disease and prior thromboembolic disease<sup>30</sup>. The D-dimer is routinely utilized clinically in diagnosing disseminated intravascular coagulation (DIC) and those with low pretest probability for deep vein thrombosis (DVT) and pulmonary embolism (PE)<sup>29</sup>.

More recently, D-dimer has been explored to identify patients thought to develop severe COVID-19 infection earlier in their course of illness. Elevated D-dimer level was discovered in about 36%-47% of hospitalized patients with COVID-19 infection, the majority of whom are those with severe COVID-19 infection<sup>31</sup>. A prior meta-analysis comprising of 4 studies showed a higher D-dimer level in patients with severe COVID-19 infection compared to those with the non-severe disease<sup>32</sup>. However, this meta-analysis was limited by relatively smaller sample size. Also, it did not answer an important question regarding the prognostic value of D-dimer in predicting severe COVID-19 infection and mortality. Our meta-analysis comprising of 18 studies evaluated the prognostic role of D-dimer in COVID-19 and is the

Shah et al

largest to date to the best of our knowledge. The key findings of our pooled analysis are: 1) the D-dimer levels were higher in patients with severe COVID-19 infection and those who succumbed to death compared to non-severe disease and those who survived, respectively after adjusting for age, comorbid condition, CRP levels; 2) patients with elevated D-dimer levels were at increased risk of developing severe COVID-19 infection and increased all-cause mortality compared to those with normal D-dimer levels.

Zhou et al.<sup>13</sup> reported that D-dimer level >1 mg/L on admission was independently associated with increased odds of mortality, findings that echoes in our pooled analysis as well. Also, patients with advanced age, higher Sequential Organ Failure Assessment (SOFA) score, elevated troponin, and B-type natriuretic peptide (BNP) have been associated with poor outcomes and mortality in COVID-19 infection<sup>13, 33, 34</sup>. Furthermore, using a higher cutoff value of D-dimer (levels > 2mg/L) predicted in-hospital mortality even better as noted by Zhang et al.<sup>17</sup> with a sensitivity of 92.3% and a specificity of 83.3% after adjusting for age, gender and comorbidities. Besides, studies have shown that rising D-dimer levels during the course of hospitalization are associated with worst long term outcomes<sup>12, 13</sup>. Additionally, COVID-19 patients with one or more comorbidities [HTN, DM, and cardiovascular diseases] are associated with adverse outcomes (i.e. severe COVID -19 disease and/or mortality)<sup>35-37</sup>. In our pooled analysis, patients with severe COVID-19 infection had significantly elevated D-dimer levels, with an increasing prevalence of HTN, DM, and CAD.

There has been upcoming evidence regarding an increased incidence of venous thromboembolic events (VTE), including DVT and PE in patients with severe COVID-19 infection<sup>38</sup>. Besides, disseminated intravascular coagulation (DIC) has been increasingly reported in these patients. Tang et al. found a 3.5-fold increase in D-dimer levels in those who

Shah et al

died and 71% of them met the International Society on Thrombosis and Hemostasis (ISTH) criteria for DIC compared to 0.6% only among those who survived<sup>39</sup>. Similarly, another study proposed that D-dimer level >1.5mg/L may help detect VTE events with a sensitivity of 85.0% and specificity of 88.5%, however, results should be interpreted with caution due to small sample size and lack of external validation<sup>40</sup>. It is unclear at this time if this is a direct consequence of SARS-CoV-2 infection or a due to cytokine storm resulting in systemic inflammatory response syndrome (SIRS), as seen in other viral infections<sup>41-44</sup>. A similar pattern of changes in coagulation cascade with increased prothrombotic state and incidences of DVT and PE were also noted with coronavirus responsible for Middle Eastern Respiratory Syndrome (MERS-CoV) and SARS-CoV-1<sup>45</sup>. The risk of VTE is generally high in critically ill patients, but the risk appears to be higher in patients infected with SARS-CoV-2.

Due to several reasons for D-dimer elevation in these patients, imaging studies to diagnose DVT or PE should only be pursued if clinically warranted<sup>40</sup>. High clinical suspicion for DVT or PE is warranted in patients with elevated D-Dimer (more so in > 2mg/dl), as failure to treat may result in adverse clinical outcomes<sup>17</sup>. Thus, it is possible that patients who remained untreated for this catastrophe condition, accounted for adverse clinical outcomes as noted in our pooled analysis. However, no such information was available from the studies included in our analysis to evaluate for this difference. Also, performing imaging like CT angiogram of the chest can often be challenging in these patients due to isolation precautions and unstable hemodynamics, inability to administer intravenous contrast due to acute kidney injury and proning. In such cases, identification of new right ventricular dysfunction and/or enlargement on transthoracic echocardiogram can be useful. Perhaps, empirically treating all COVID-19 patients with intermediate or full (therapeutic) doses of anticoagulation to prevent

Shah et al

microvascular thrombosis<sup>14, 46</sup> might be beneficial (provided a thorough risk-benefit assessment given these patients are also at risk of spontaneous bleeding) (however, our study was not designed to assess this difference). Besides that, it remains unclear at this time regarding the optimal dosing and duration in this patient population and hence needs to be explored further. Although, extended DVT prophylaxis with oral anticoagulation at discharge (for up to 45 days) may be reasonable in patients at higher risk for the thromboembolic event (i.e. active malignancy, immobility and elevated D-dimer level > two times the upper limits of normal) and lower bleeding risk<sup>47, 48</sup>. Thus, using D-dimer levels as a surrogate marker for disease severity and underlying thromboembolic disease, especially, in COVID-19 patients who cannot get dedicated imaging might be beneficial.

Our study has a few important limitations. First, all studies included in our meta-analysis were from China, while the United States and Europe have the majority of COVID-19 cases currently. However, the preliminary reports from the United States and Europe have shown similar trends in COVID-19 infection in terms of clinical presentation and outcomes<sup>5, 49</sup>. Our pooled analysis provides the best available data regarding trends of D-dimer levels in patients with COVID-19 infection and the likelihood of developing severe infection or mortality in patients with elevated D-dimer levels. Secondly, all studies included in our analysis were either prospective or retrospective reports, which is currently the best available evidence; and, therefore, subject to potential confounding and publication bias. Third, significant heterogeneity was observed between studies in our pooled analysis. Fourth, details on anticoagulation or trends of D-dimer over the course of hospitalization were not available. Finally, patient-level data to perform additional, detailed analyses are not available.

Shah et al

## **Conclusion**

Our meta-analysis demonstrates that patients with COVID-19 presenting with elevated D-dimer levels have an increased risk of severe disease and mortality.

Shah et al

## References

1. Wang C, Horby PW, Hayden FG, Gao GF. A novel coronavirus outbreak of global health concern. *Lancet*. 2020;395:470-473
2. Coronavirus disease 2019 (covid-19) situation report – 95. 2020; Available at: [https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200424-sitrep-95-covid-19.pdf?sfvrsn=e8065831\\_4](https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200424-sitrep-95-covid-19.pdf?sfvrsn=e8065831_4). Accessed on 29<sup>th</sup> April, 2020
3. Guo YR, Cao QD, Hong ZS, Tan YY, Chen SD, Jin HJ, Tan KS, Wang DY, Yan Y. The origin, transmission and clinical therapies on coronavirus disease 2019 (covid-19) outbreak - an update on the status. *Mil Med Res*. 2020;7:11
4. Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, Qiu Y, Wang J, Liu Y, Wei Y, Xia J, Yu T, Zhang X, Zhang L. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in wuhan, china: A descriptive study. *Lancet*. 2020;395:507-513
5. Onder G, Rezza G, Brusaferro S. Case-fatality rate and characteristics of patients dying in relation to covid-19 in italy. *JAMA*. 2020
6. Bhatraju PK, Ghassemieh BJ, Nichols M, Kim R, Jerome KR, Nalla AK, Greninger AL, Pipavath S, Wurfel MM, Evans L, Kritek PA, West TE, Luks A, Gerbino A, Dale CR, Goldman JD, O'Mahony S, Mikacenic C. Covid-19 in critically ill patients in the seattle region - case series. *N Engl J Med*. 2020
7. Moher D, Liberati A, Tetzlaff J, Altman DG, Group P. Preferred reporting items for systematic reviews and meta-analyses: The prisma statement. *Ann Intern Med*. 2009;151:264-269, W264

Shah et al

8. DerSimonian R, Laird N. Meta-analysis in clinical trials. *Control Clin Trials*. 1986;7:177-188
9. Wan X, Wang W, Liu J, Tong T. Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range. *BMC Med Res Methodol*. 2014;14:135
10. Higgins JP, Altman DG, Gotzsche PC, Juni P, Moher D, Oxman AD, Savovic J, Schulz KF, Weeks L, Sterne JA, Cochrane Bias Methods G, Cochrane Statistical Methods G. The cochrane collaboration's tool for assessing risk of bias in randomised trials. *BMJ*. 2011;343:d5928
11. Du RH, Liang LR, Yang CQ, Wang W, Cao TZ, Li M, Guo GY, Du J, Zheng CL, Zhu Q, Hu M, Li XY, Peng P, Shi HZ. Predictors of mortality for patients with covid-19 pneumonia caused by sars-cov-2: A prospective cohort study. *Eur Respir J*. 2020
12. Cao J, Tu WJ, Cheng W, Yu L, Liu YK, Hu X, Liu Q. Clinical features and short-term outcomes of 102 patients with corona virus disease 2019 in wuhan, china. *Clin Infect Dis*. 2020
13. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, Xiang J, Wang Y, Song B, Gu X, Guan L, Wei Y, Li H, Wu X, Xu J, Tu S, Zhang Y, Chen H, Cao B. Clinical course and risk factors for mortality of adult inpatients with covid-19 in wuhan, china: A retrospective cohort study. *Lancet*. 2020;395:1054-1062
14. Tang N, Bai H, Chen X, Gong J, Li D, Sun Z. Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy. *J Thromb Haemost*. 2020



Shah et al

15. Wang L, He W, Yu X, Hu D, Bao M, Liu H, Zhou J, Jiang H. Coronavirus disease 2019 in elderly patients: Characteristics and prognostic factors based on 4-week follow-up. *J Infect.* 2020
16. Zhang F, Yang D, Li J, Gao P, Chen T, Cheng Z, Cheng K, Fang Q, Pan W, Yi C, Fan H, Wu Y, Li L, Fang Y, Liu J, Tian G, He L. Myocardial injury is associated with in-hospital mortality of confirmed or suspected covid-19 in wuhan, china: A single center retrospective cohort study. *medRxiv.* 2020:2020.2003.2021.20040121
17. Zhang L, Yan X, Fan Q, Liu H, Liu X, Liu Z, Zhang Z. D-dimer levels on admission to predict in-hospital mortality in patients with covid-19. *J Thromb Haemost.* 2020
18. Hu L, Chen S, Fu Y, Gao Z, Long H, Ren H-w, Zuo Y, Li H, Wang J, Xv Q-b, Yu W-x, Liu J, Shao C, Hao J-j, Wang C-z, Ma Y, Wang Z, Yanagihara R, Wang J-m, Deng Y. Risk factors associated with clinical outcomes in 323 covid-19 patients in wuhan, china. *medRxiv.* 2020:2020.2003.2025.20037721
19. Chen G, Wu D, Guo W, Cao Y, Huang D, Wang H, Wang T, Zhang X, Chen H, Yu H, Zhang X, Zhang M, Wu S, Song J, Chen T, Han M, Li S, Luo X, Zhao J, Ning Q. Clinical and immunological features of severe and moderate coronavirus disease 2019. *J Clin Invest.* 2020
20. Deng Q, Hu B, Zhang Y, Wang H, Zhou X, Hu W, Cheng Y, Yan J, Ping H, Zhou Q. Suspected myocardial injury in patients with covid-19: Evidence from front-line clinical observation in wuhan, china. *Int J Cardiol.* 2020
21. Zhang JJ, Dong X, Cao YY, Yuan YD, Yang YB, Yan YQ, Akdis CA, Gao YD. Clinical characteristics of 140 patients infected with sars-cov-2 in wuhan, china. *Allergy.* 2020

Shah et al

22. Lu H, Ai J, Shen Y, Li Y, Li T, Zhou X, Zhang H, Zhang Q, Ling Y, Wang S, Qu H, Gao Y, Li Y, Yu K, Zhu D, Zhu H, Tian R, Zeng M, Li Q, Song Y, Li X, Xu J, Xu J, Mao E, Hu B, Li X, Zhu L, Zhang W. A descriptive study of the impact of diseases control and prevention on the epidemics dynamics and clinical features of sars-cov-2 outbreak in shanghai, lessons learned for metropolis epidemics prevention. *medRxiv*. 2020:2020.2002.2019.20025031
23. Ma K-L, Liu Z-H, Cao C-f, Liu M-K, Liao J, Zou J-B, Kong L-X, Wan K-Q, Zhang J, Wang Q-B, Tian W-G, Qin G-M, Zhang L, Luan F-J, Li S-L, Hu L-B, Li Q-L, Wang H-Q. Covid-19 myocarditis and severity factors : an adult cohort study. *medRxiv*. 2020:2020.2003.2019.20034124
24. Qian GQ, Yang NB, Ding F, Ma AHY, Wang ZY, Shen YF, Shi CW, Lian X, Chu JG, Chen L, Wang ZY, Ren DW, Li GX, Chen XQ, Shen HJ, Chen XM. Epidemiologic and clinical characteristics of 91 hospitalized patients with covid-19 in zhejiang, china: A retrospective, multi-centre case series. *QJM*. 2020
25. Wan S, Xiang Y, Fang W, Zheng Y, Li B, Hu Y, Lang C, Huang D, Sun Q, Xiong Y, Huang X, Lv J, Luo Y, Shen L, Yang H, Huang G, Yang R. Clinical features and treatment of covid-19 patients in northeast chongqing. *J Med Virol*. 2020
26. Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, Liu L, Shan H, Lei CL, Hui DSC, Du B, Li LJ, Zeng G, Yuen KY, Chen RC, Tang CL, Wang T, Chen PY, Xiang J, Li SY, Wang JL, Liang ZJ, Peng YX, Wei L, Liu Y, Hu YH, Peng P, Wang JM, Liu JY, Chen Z, Li G, Zheng ZJ, Qiu SQ, Luo J, Ye CJ, Zhu SY, Zhong NS, China Medical Treatment Expert Group for C. Clinical characteristics of coronavirus disease 2019 in china. *N Engl J Med*. 2020

Shah et al

27. Cai Q, Huang D, Ou P, Yu H, Zhu Z, Xia Z, Su Y, Ma Z, Zhang Y, Li Z, Qing H, Fu Y, Chen J, Lei L. 2019-ncov pneumonia in a normal work infectious diseases hospital besides hubei province, china. 2020; Available at: <https://ssrn.com/abstract=3542163>; Accessed on 29<sup>th</sup> April, 2020
28. Ji D, Zhang D, Chen Z, Xu Z, Zhao P, Zhang M, Zhang L, Cheng G, Wang Y, Yang G, Liu H, Li B, Ji J, Lau G, Qin E. Clinical characteristics predicting progression of covid-19 2020; Available at: <https://ssrn.com/abstract=3539674>; Accessed on 29<sup>th</sup> April, 2020
29. Weitz JI, Fredenburgh JC, Eikelboom JW. A test in context: D-dimer. *J Am Coll Cardiol.* 2017;70:2411-2420
30. Kabrhel C, Mark Courtney D, Camargo CA, Jr., Plewa MC, Nordenholz KE, Moore CL, Richman PB, Smithline HA, Beam DM, Kline JA. Factors associated with positive d-dimer results in patients evaluated for pulmonary embolism. *Acad Emerg Med.* 2010;17:589-597
31. Lippi G, Plebani M. Laboratory abnormalities in patients with covid-2019 infection. *Clin Chem Lab Med.* 2020
32. Lippi G, Favaloro EJ. D-dimer is associated with severity of coronavirus disease 2019: A pooled analysis. *Thromb Haemost.* 2020
33. Gao L, Jiang D, Wen XS, Cheng XC, Sun M, He B, You LN, Lei P, Tan XW, Qin S, Cai GQ, Zhang DY. Prognostic value of nt-probnp in patients with severe covid-19. *Respir Res.* 2020;21:83
34. Li JW, Han TW, Woodward M, Anderson CS, Zhou H, Chen YD, Neal B. The impact of 2019 novel coronavirus on heart injury: A systemic review and meta-analysis. *Prog Cardiovasc Dis.* 2020

Shah et al

35. Wang B, Li R, Lu Z, Huang Y. Does comorbidity increase the risk of patients with covid-19: Evidence from meta-analysis. *Aging (Albany NY)*. 2020;12:6049-6057
36. Huang I, Lim MA, Pranata R. Diabetes mellitus is associated with increased mortality and severity of disease in covid-19 pneumonia - a systematic review, meta-analysis, and meta-regression. *Diabetes Metab Syndr*. 2020;14:395-403
37. Lippi G, Wong J, Henry BM. Hypertension and its severity or mortality in coronavirus disease 2019 (covid-19): A pooled analysis. *Pol Arch Intern Med*. 2020
38. Zhang Y, Xiao M, Zhang S, Xia P, Cao W, Jiang W, Chen H, Ding X, Zhao H, Zhang H, Wang C, Zhao J, Sun X, Tian R, Wu W, Wu D, Ma J, Chen Y, Zhang D, Xie J, Yan X, Zhou X, Liu Z, Wang J, Du B, Qin Y, Gao P, Qin X, Xu Y, Zhang W, Li T, Zhang F, Zhao Y, Li Y, Zhang S. Coagulopathy and antiphospholipid antibodies in patients with covid-19. *N Engl J Med*. 2020;382:e38
39. Tang N, Li D, Wang X, Sun Z. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. *J Thromb Haemost*. 2020;18:844-847
40. Bikdeli B, Madhavan MV, Jimenez D, Chuich T, Dreyfus I, Driggin E, Nigoghossian C, Ageno W, Madjid M, Guo Y, Tang LV, Hu Y, Giri J, Cushman M, Quere I, Dimakakos EP, Gibson CM, Lippi G, Favaloro EJ, Fareed J, Caprini JA, Tafur AJ, Burton JR, Francese DP, Wang EY, Falanga A, McLintock C, Hunt BJ, Spyropoulos AC, Barnes GD, Eikelboom JW, Weinberg I, Schulman S, Carrier M, Piazza G, Beckman JA, Steg PG, Stone GW, Rosenkranz S, Goldhaber SZ, Parikh SA, Monreal M, Krumholz HM, Konstantinides SV, Weitz JI, Lip GYH. Covid-19 and thrombotic or thromboembolic

Shah et al

- disease: Implications for prevention, antithrombotic therapy, and follow-up. *J Am Coll Cardiol*. 2020
41. Borges AH, O'Connor JL, Phillips AN, Baker JV, Vjecha MJ, Losso MH, Klinker H, Lopardo G, Williams I, Lundgren JD, Group ISS, Group ES, Committee SS. Factors associated with d-dimer levels in hiv-infected individuals. *PLoS One*. 2014;9:e90978
  42. Ramacciotti E, Agati LB, Aguiar VCR, Wolosker N, Guerra JC, de Almeida RP, Alves JC, Lopes RD, Wakefield TW, Comerota AJ, Walenga J, Fareed J. Zika and chikungunya virus and risk for venous thromboembolism. *Clin Appl Thromb Hemost*. 2019;25:1076029618821184
  43. Smither SJ, O'Brien LM, Eastaugh L, Woolley T, Lever S, Fletcher T, Parmar K, Hunt BJ, Watts S, Kirkman E. Haemostatic changes in five patients infected with ebola virus. *Viruses*. 2019;11
  44. Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ, Hlh Across Speciality Collaboration UK. Covid-19: Consider cytokine storm syndromes and immunosuppression. *Lancet*. 2020;395:1033-1034
  45. Giannis D, Ziogas IA, Gianni P. Coagulation disorders in coronavirus infected patients: Covid-19, sars-cov-1, mers-cov and lessons from the past. *J Clin Virol*. 2020;127:104362
  46. Klok FA, Kruip M, van der Meer NJM, Arbous MS, Gommers D, Kant KM, Kaptein FHJ, van Paassen J, Stals MAM, Huisman MV, Endeman H. Incidence of thrombotic complications in critically ill icu patients with covid-19. *Thromb Res*. 2020
  47. Spyropoulos AC, Lipardi C, Xu J, Peluso C, Spiro TE, De Sanctis Y, Barnathan ES, Raskob GE. Modified improve vte risk score and elevated d-dimer identify a high venous

Shah et al

- thromboembolism risk in acutely ill medical population for extended thromboprophylaxis. *TH Open*. 2020;4:e59-e65
48. Cohen AT, Spiro TE, Spyropoulos AC, Desanctis YH, Homering M, Buller HR, Haskell L, Hu D, Hull R, Mebazaa A, Merli G, Schellong S, Tapson VF, Burton P, Group MS. D-dimer as a predictor of venous thromboembolism in acutely ill, hospitalized patients: A subanalysis of the randomized controlled magellan trial. *J Thromb Haemost*. 2014;12:479-487
49. Richardson S, Hirsch JS, Narasimhan M, Crawford JM, McGinn T, Davidson KW, and the Northwell C-RC, Barnaby DP, Becker LB, Chelico JD, Cohen SL, Cookingham J, Coppa K, Diefenbach MA, Dominello AJ, Duer-Hefele J, Falzon L, Gitlin J, Hajizadeh N, Harvin TG, Hirschwerk DA, Kim EJ, Kozel ZM, Marrast LM, Mogavero JN, Osorio GA, Qiu M, Zanos TP. Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with covid-19 in the new york city area. *JAMA*. 2020

Shah et al

## Figure legends

**Table 1:** Baseline characteristics of studies included in the meta-analysis comparing COVID-19 infected patients who died versus who survived

**Table 2:** Baseline characteristics of studies included in the meta-analysis comparing severe versus non-severe COVID-19 infected patients

**Table 3:** Meta regression of baseline characteristics with mean difference in D-dimer levels in COVID-19 patients – dead versus survived

**Table 4.** Meta regression of baseline characteristics with mean difference in D-dimer levels in severe versus non-severe COVID-19 infected patients

**Supplement Table 1:** PRISMA checklist

**Supplement Table 2:** Risk of bias assessment of studies included in our meta-analysis using Newcastle-Ottawa Scale

**Figure 1:** Flow Diagram illustrating the systematic search of studies

**Figure 2: D-Dimer levels.** The Forest plot for pooled difference in mean D-Dimer levels in dead versus survived COVID -19 patients.

**Figure 3: All-cause mortality.** The Forest plot shows the outcomes of the individual trials as well as the aggregate.

**Figure 4: Disease severity.** (A) The Forest plot for pooled difference in mean D-Dimer levels in severe versus non-severe COVID-19 patients, followed by random-effects meta-regression analysis plots depicting the relationship between mean differences in D-Dimer levels (on y-axis) and (B) Coronary Artery disease (CAD) and (C) C-Reactive Protein (CRP). Each included study is represented by a circle, the size of which is proportional to its respective weight in the analysis. The line indicates the predicted effects (regression line). There was significant association between CAD ( $\beta = 0.8$ ,  $P = 0.02$ ), and CRP levels ( $\beta = 0.02$ ,  $P = 0.03$ ) and mean differences in D-Dimer levels.

**Figure 5:** The Forest plot demonstrating the risk ratio of positive D-Dimer with severity.

**Supplement Figure 1: D-Dimer levels.** The funnel plot of studies included in the analysis assessing D-dimer levels in dead versus survived COVID -19 patients

**Supplement Figure 2: All-cause mortality.** The funnel plot of studies assessing the association of elevated D-dimer and all-cause mortality in COVID-19 patients.

**Supplement Figure 3:** The funnel plot of studies included in the analysis assessing D-dimer levels in severe versus non-severe COVID-19 infected patients.


Shah et al

**Supplement Figure 4:** The funnel plot of studies assessing the association of elevated D-dimer and COVID-19 disease severity.




Shah et al

**Figure 1:** Flow diagram illustrating the systematic search of studies




Shah et al

**Figure 2. D-Dimer levels.** The Forest plot for pooled difference in mean D-Dimer levels in dead versus survived COVID -19 patients






Shah et al

**Figure 3. All-cause mortality.** The Forest plot shows the outcomes of the individual trials as well as the aggregate.




Shah et al

**Figure 4. Disease severity.** (A) The Forest plot for pooled difference in mean D-Dimer levels in severe versus non-severe COVID-19 patients, followed by random-effects meta-regression analysis plots depicting the relationship between mean differences in D-Dimer levels (on y-axis) and (B) Coronary Artery disease (CAD) and (C) C-Reactive Protein (CRP). Each included study is represented by a circle, the size of which is proportional to its respective weight in the analysis. The line indicates the predicted effects (regression line). There was significant association between CAD ( $\beta = 0.8$ ,  $P = 0.02$ ), and CRP levels ( $\beta = 0.02$ ,  $P = 0.03$ ) and mean differences in D-Dimer levels.



Shah et al

**Figure 5.** The Forest plot demonstrating the risk ratio of positive D-Dimer with severity



**Table 1.** Baseline characteristics of studies included in the meta-analysis comparing COVID-19 infected patients who died versus who survived

Study Name	Study Type	Country	Study Period	Age (Y)	Male	Groups	N	Diabetes	Hypertension	Coronary Artery Disease	Acute Cardiac Injury	Arrhythmias	Shock
Zhang, L.	Retrospective	China	Jan 12- March 15, 2020	62 (IQR 48-69)	169	<b>Overall</b>	343	47	76	19	NR	NR	NR
Wang, L.	Retrospective	China	Jan 1- Feb 6, 2020	69(IQR 65-76)	166	<b>Survived</b>	274	43	106	NR	31	22	5
						<b>Dead</b>	65	11	32	NR	39	13	3
Tang, N.	Retrospective	China	Jan 1-Feb 13, 2020	65.1±12.0	268	<b>Survived</b>	315	NR	NR	NR	NR	NR	NR
						<b>Dead</b>	134	NR	NR	NR	NR	NR	NR
Zhou, F.	Retrospective	China	Dec 29, 2019 -Feb 1, 2020	56(IQR 46-67)	119	<b>Survived</b>	137	19	32	2	1	NR	NR
						<b>Dead</b>	54	17	26	13	2	NR	38
Du, R.	Prospective	China	Dec 25, 2019- Feb 7, 2020	57.6 ± 13.7	97	<b>Survived</b>	158	27	45	NR	NR	NR	NR
						<b>Dead</b>	21	6	13	NR	NR	NR	NR
Cao, J.	Retrospective	China	Jan 3- Feb 1, 2020	54(IQR 37-67)	53	<b>Survived</b>	85	5	17	NR	3	6	3
						<b>Dead</b>	17	6	11	NR	12	12	7
Zhang, F.	Retrospective	China	Dec 25, 2019- Feb 15, 2020	70.58±13.38	33	<b>Survived</b>	31	5	20	9	NR	NR	NR
						<b>Dead</b>	17	5	12	4	NR	NR	NR

N = number; Y = years; IQR = interquartile range; NR = not reported

**Table 2.** Baseline characteristics of studies included in the meta-analysis comparing severe versus non-severe COVID-19 infected patients

Study Name	Study Type	Country	Study Period	Age (Y)	Male	Groups	N	Diabetes	Hypertension	Coronary Artery Disease	Acute Cardiac Injury	Arrhythmias	Shock
Deng, Q.	Retrospective	China	Jan 6- Feb 20, 2020	65(IQR 49-70.8)	57	Non-severe	45	5	12	4	3	NR	NR
						Severe	67	14	24	11	9	NR	NR
Chen, G.	Retrospective	China	Dec-Jan 27, 2020	56(IQR 50-65)	17	Non-severe	10	1	1	NR	NR	NR	NR
						Severe	11	2	4	NR	1	NR	1
Zhang, J.	Retrospective	China	Jan 16-Feb 3, 2020	57 (range 25-87)	71	Non-severe	82	9	20	3	NR	NR	NR
						Severe	58	8	22	4	NR	NR	NR
Qian, G.	Retrospective	China	Jan 20-Feb 11, 2020	50(IQR 36.5-57)	37	Non-severe	82	8	15	NR	NR	NR	NR
						Severe	9			NR	NR	NR	NR
Cai, Q.	Retrospective	China	Jan 11-Feb 09, 2020	47(IQR 33-61)	149	Non-severe	240	19	38	NR	5	NR	NR
						Severe	58			NR	5	NR	NR
Ji, D.	Prospective	China	Jan 20-Feb 16, 2020	43.6±17.1	31	Non-severe	34	NR	NR	NR	NR	NR	NR

medRxiv preprint doi: <https://doi.org/10.1101/2020.04.22.20085407>; this version posted May 5, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.

						<b>Severe</b>	15	NR	NR	NR	NR	NR	NR
Lu, H.	Retrospective	China	Jan 20- Feb 19, 2020	NR	NR	<b>Non-severe</b>	243	15	42	10	NR	NR	NR
						<b>Severe</b>	22	6	10	4	NR	NR	NR
Ma, K.	Retrospective	China	Jan 21-March 2, 2020	48(IQR 42.3-62.5)	48	<b>Non-severe</b>	64	3	8	NR	NR	NR	NR
						<b>Severe</b>	20	7	4	NR	NR	NR	NR
Hu, L.	Retrospective	China	Jan 8- Feb 20, 2020	61(range 23-91)	166	<b>Non-severe</b>	151	14	39	NR	NR	18	4
						<b>Severe</b>	172	33	66	NR	NR	80	39
Wan, S.	Retrospective	China	Jan 23- Feb 8, 2020	47(IQR 36-55)	72	<b>Non-severe</b>	95	3	9	NR	NR	NR	0
						<b>Severe</b>	40	9	4	NR	NR	NR	1
Guan, W.	Retrospective	China	Dec 11, 2019- Jan 29, 2020	47(IQR 35-58)	637	<b>Non-severe</b>	926	53	124	17	NR	NR	1
						<b>Severe</b>	173	28	41	10	NR	NR	11

N = number; Y = years; IQR = interquartile range; NR = not reported



**Table 3:** Meta regression of baseline characteristics with mean difference in D-dimer levels in COVID-19 patients – dead versus survived.

Dead vs survived COVID-19		Meta regression					
	<i>Difference in Means (95% CI)</i>	<i>Age</i>	<i>Male</i>	<i>Hypertension</i>	<i>Diabetes</i>	<i>CAD</i>	<i>Troponin</i>
D-Dimer levels	6.13 (4.16 – 8.11), P<0.001	$\beta$ : 0.02, p=0.91	$\beta$ : 0.05, p=0.62	$\beta$ : -0.002, p=0.98	$\beta$ : 0.15, p=0.82	$\beta$ : -0.12, p=0.25	$\beta$ : 201.41, p=0.53

CI- confidence interval, CAD- coronary artery disease

medRxiv preprint doi: <https://doi.org/10.1101/2020.04.29.20085407>; this version posted May 5, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.

**Table 4:** Meta regression of baseline characteristics with mean difference in D-dimer levels in severe versus non-severe COVID-19 infected patients

Severe vs non-severe COVID-19		Meta regression						
	Difference in Means (95% CI)	Age	Male	Hypertension	Diabetes	CAD*	CRP*	Troponin
D-Dimer levels	0.54 (0.28 – 0.80), P<0.001	β: 0.03, p=0.31	β: 0.008, p=0.68	β: 0.03, p=0.2	β: -0.01, p=0.84	β: 0.8, p=0.02	β: 0.02, p=0.001	β: 105.63, p=0.06

CI- confidence interval, CAD- coronary artery disease, CRP- C reactive protein, \* indicates statistically significant value.

medRxiv preprint doi: <https://doi.org/10.1101/2020.04.29.20085407>; this version posted May 5, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.